한글목차

우블리툭시맙 시장 규모는 최근 급성장하고 있습니다. 2025년 12억 5,000만 달러에서 2026년에는 14억 1,000만 달러에 이르고, CAGR 12.6%의 성장이 전망되고 있습니다. 지난 수년간의 성장은 단일클론항체 개발의 발전, B세포 관련 질환의 유병률 증가, 생물학적 제제 생산 능력 확대, CD20 치료제의 규제 승인, 면역종양학 연구의 진전에 기인하는 것으로 보입니다.

우블리툭시맙 시장 규모는 향후 몇 년간 급성장이 전망됩니다. 2030년에는 22억 4,000만 달러에 이르고, CAGR은 12.3%를 나타낼 전망입니다. 예측 기간의 성장 요인으로는 차세대 항체 개발 증가, 치료의 지속성과 안전성에 대한 관심 증가, 자가면역질환 영역으로의 확대, 생물학적 제제 제조 기술 혁신에 대한 투자 증가, 정밀 면역요법 도입 확대 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 CD20 표적 단일클론항체 채용 확대, B세포 고갈 치료에 대한 관심 증가, 면역조절 치료의 사용 증가, 항체 병용요법 확대, 항체 설계 최적화 강화 등을 꼽을 수 있습니다.

자가면역질환의 유병률 증가는 향후 몇 년간 우블리툭시맙 시장의 성장을 견인할 것으로 예측됩니다. 자가면역질환은 면역체계가 건강한 세포를 잘못 공격하거나 혈액세포의 생산과 기능이 손상된 상태를 말합니다. 이러한 질병 발생률 증가는 주로 진단 능력의 향상과 인식 증가에 기인하며, 의료 시스템이 고급 검사 방법과 확장된 선별 검사 프로그램을 통해 기존에 진단되지 않은 사례를 보다 효과적으로 감지할 수 있게 되었기 때문입니다. 우블리툭시맙은 당쇄공학을 적용한 항CD20 단일클론항체로서 병원성 B세포를 선택적으로 제거하여 자가면역질환의 관리를 돕고 비정상적인 면역활동과 악성세포의 증식을 억제합니다. 예를 들어, 호주에 본부를 둔 비영리단체 'Arthritis Australia'에 따르면 2025년에는 남성 약 21만 2,136명, 여성 약 36만 2,137명이 류마티스 관절염(RA)을 앓을 것으로 예상되며, 2040년까지 남성 약 28만 40명, 여성 약 47만 9, 828명으로 증가할 것으로 예측됩니다. 828명으로 증가할 것으로 예측됩니다. 그 결과, 자가면역질환의 유병률 증가가 우블리툭시맙 시장의 성장을 가속하고 있습니다.

우블리툭시맙 시장의 주요 기업들은 효능 향상, 부작용 감소, 환자 편의성 향상을 위해 차세대 단일클론항체 등 혁신적인 제품 개발에 주력하고 있습니다. 이들 차세대 단일클론항체는 표적화, 효능, 안전성 등의 특성이 강화된 설계 개선 버전으로, 치료 효과 향상, 부작용 감소, 투여 계획의 간소화를 실현합니다. 예를 들어, 2023년 1월 미국 바이오 제약사 TG Therapeutics Inc.는 재발성 다발성 경화증 성인 환자를 위한 치료제 'BRIUMVI(우블리툭시맙-xiiy)'를 발표했습니다. 이 약은 1시간 내 투약과 종합적인 환자 지원 프로그램을 통해 치료 접근성과 복약 순응도를 높인 것이 특징입니다. 이 약은 당쇄공학이 적용된 항CD20 단일클론항체로서 B세포를 효과적으로 제거하여 재발률과 질병 활성을 낮추는 동시에 기존 치료법에 비해 잠재적인 부작용을 줄이고, 보다 편리한 투약 스케줄을 실현합니다. 작용기전은 CD20을 발현하는 B세포의 특정 에피토프에 결합하여 항체 의존성 세포손상(ADCC) 및 세포사멸을 통한 정밀한 B세포 제거를 유도함으로써 다발성 경화증을 유발하는 자가면역반응을 조절하는 것입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 세계 시장 경쟁 벤치마킹과 대시보드

제37장 주요 인수합병(M&A)

제39장 시장 잠재력이 높은 국가, 부문, 전략

제40장 부록

영문목차

Ublituximab is a monoclonal antibody engineered to target the CD20 protein present on the surface of B-cells, helping to decrease abnormal or overactive B-cell activity. It functions by attaching to these cells and promoting their elimination through immune system processes such as antibody-dependent cellular cytotoxicity. It is primarily developed for the treatment of certain blood cancers, helping to regulate immune responses and manage disease progression effectively.

The primary formulation types of ublituximab include intravenous (IV) and pre-filled syringes. Intravenous administration delivers medications or fluids directly into the bloodstream through a vein, enabling rapid and controlled treatment. Ublituximab is indicated for conditions such as chronic lymphocytic leukemia, multiple sclerosis, and non-Hodgkin lymphoma. It is supplied through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and is used by end-users such as hospitals, specialty clinics, and research institutes.

Tariffs are impacting the ublituximab market by increasing costs of imported biologic raw materials, cell culture media, specialized manufacturing equipment, and cold-chain logistics components. North America and Europe are most affected due to reliance on global biologics supply chains, while Asia-Pacific faces cost pressures in biologic exports. These tariffs are increasing production and distribution costs for monoclonal antibody therapies. However, they are also driving investment in domestic biologics manufacturing facilities, localized supply chains, and improved production efficiencies to support long-term market stability.

The ublituximab market research report is one of a series of new reports from The Business Research Company that provides ublituximab market statistics, including ublituximab industry global market size, regional shares, competitors with a ublituximab market share, detailed ublituximab market segments, market trends and opportunities, and any further data you may need to thrive in the ublituximab industry. This ublituximab market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ublituximab market size has grown rapidly in recent years. It will grow from $1.25 billion in 2025 to $1.41 billion in 2026 at a compound annual growth rate (CAGR) of 12.6%. The growth in the historic period can be attributed to advances in monoclonal antibody development, increasing prevalence of b-cell related disorders, expansion of biologics manufacturing capacity, regulatory approvals for cd20 therapies, growth in immuno-oncology research.

The ublituximab market size is expected to see rapid growth in the next few years. It will grow to $2.24 billion in 2030 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to increasing development of next-generation antibodies, rising focus on treatment durability and safety, expansion into autoimmune indications, growing investments in biologics manufacturing innovation, increasing adoption of precision immunotherapy. Major trends in the forecast period include increasing adoption of cd20-targeted monoclonal antibodies, rising focus on b-cell depletion therapies, growing use of immune-modulating treatments, expansion of combination antibody regimens, enhanced optimization of antibody engineering.

The increasing prevalence of autoimmune disorders is expected to drive the growth of the ublituximab market in the coming years. Autoimmune disorders are conditions in which the immune system mistakenly attacks healthy cells or where blood cell production and function are disrupted. The rising occurrence of these disorders is largely attributed to enhanced diagnostic capabilities and greater awareness, as healthcare systems are now better able to detect previously undiagnosed cases through advanced testing methods and expanded screening programs. Ublituximab, a glycoengineered anti-CD20 monoclonal antibody, helps manage autoimmune disorders by selectively depleting pathogenic B cells, thereby reducing abnormal immune activity and malignant cell proliferation. For example, in February 2024, according to Arthritis Australia, a non-profit organization based in Australia, an estimated 212,136 males and 362,137 females are projected to have rheumatoid arthritis (RA) in 2025, with these numbers expected to increase by 2040 to approximately 280,040 males and 479,828 females. Consequently, the rising prevalence of autoimmune disorders is fueling the growth of the ublituximab market.

Major companies in the ublituximab market are prioritizing the development of innovative products like next-generation monoclonal antibodies to boost efficacy, cut side effects, and increase patient convenience. These next-generation monoclonal antibodies represent engineered versions with enhanced targeting, potency, or safety features, which improve treatment outcomes, lessen side effects, and enable simpler dosing regimens. For example, in January 2023, TG Therapeutics Inc., a US-based biopharmaceutical firm, introduced BRIUMVI (ublituximab-xiiy) for treating adult patients with relapsing forms of multiple sclerosis, featuring a one-hour infusion and a comprehensive patient support program to boost accessibility and adherence. The drug is a glycoengineered anti-CD20 monoclonal antibody that effectively depletes B-cells, lowering relapse rates and disease activity in RMS patients, while reducing potential side effects and delivering a more user-friendly dosing schedule than conventional treatments. Its mechanism of action entails binding to a distinct epitope on CD20-expressing B-cells, leading to their precise depletion via antibody-dependent cellular cytotoxicity (ADCC) and apoptosis, thereby regulating the autoimmune response that drives multiple sclerosis.

In August 2023, TG Therapeutics Inc., a US-based biopharmaceutical company offering ublituximab, collaborated with Neuraxpharm Holdco S.a.r.l. to market BRIUMVI beyond the US. Through this partnership, TG Therapeutics and Neuraxpharm seek to deliver BRIUMVI to patients internationally, capitalizing on Neuraxpharm's deep expertise in European neurology and its strong footprint in more than 20 countries for a swift and successful rollout, while TG gains from initial payments, milestone payments, graduated royalties on net sales, and the option to reclaim commercial rights if control changes. Neuraxpharm Holdco S.a.r.l. is a Germany-based pharmaceutical firm focused on therapies for central nervous system (CNS) disorders.

Major companies operating in the ublituximab market are Samsung Biologics Co. Ltd., TG Therapeutics Inc.

North America was the largest region in the ublituximab market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ublituximab market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ublituximab market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ublituximab market consists of sales of azer-cel and tg-1701. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ublituximab Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses ublituximab market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ublituximab ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The ublituximab market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Formulation Type: Intravenous; Pre-Filled Syringes
• 2) By Indication: Chronic Lymphocytic Leukemia; Multiple Sclerosis; Non-Hodgkin Lymphoma
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 4) By End-User: Hospitals; Specialty Clinics; Research Institutes
• Subsegments:
• 1) By Intravenous: Single Dose Vials; Multi Dose Vials; Lyophilized Powder; Liquid Solution
• 2) By Pre Filled Syringes: Standard Pre Filled Syringes; Safety Engineered Pre Filled Syringes; Disposable Pre Filled Syringes; Reusable Pre Filled Syringes
• Companies Mentioned: Samsung Biologics Co. Ltd.; TG Therapeutics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Ublituximab Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Ublituximab Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Ublituximab Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Ublituximab Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Fintech, Blockchain, Regtech & Digital Finance
• 4.2. Major Trends
  • 4.2.1 Increasing Adoption Of Cd20-Targeted Monoclonal Antibodies
  • 4.2.2 Rising Focus On B-Cell Depletion Therapies
  • 4.2.3 Growing Use Of Immune-Modulating Treatments
  • 4.2.4 Expansion Of Combination Antibody Regimens
  • 4.2.5 Enhanced Optimization Of Antibody Engineering

5. Ublituximab Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Specialty Clinics
• 5.3 Research Institutes
• 5.4 Oncology Centers
• 5.5 Immunology Treatment Centers

6. Ublituximab Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Ublituximab Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Ublituximab PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Ublituximab Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Ublituximab Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Ublituximab Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Ublituximab Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Ublituximab Market Segmentation

• 9.1. Global Ublituximab Market, Segmentation By Formulation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Intravenous, Pre-Filled Syringes
• 9.2. Global Ublituximab Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Chronic Lymphocytic Leukemia, Multiple Sclerosis, Non-Hodgkin Lymphoma
• 9.3. Global Ublituximab Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
• 9.4. Global Ublituximab Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Specialty Clinics, Research Institutes
• 9.5. Global Ublituximab Market, Sub-Segmentation Of Intravenous, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Single Dose Vials, Multi Dose Vials, Lyophilized Powder, Liquid Solution
• 9.6. Global Ublituximab Market, Sub-Segmentation Of Pre-Filled Syringes, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Standard Pre Filled Syringes, Safety Engineered Pre Filled Syringes, Disposable Pre Filled Syringes, Reusable Pre Filled Syringes

10. Ublituximab Market Regional And Country Analysis

• 10.1. Global Ublituximab Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Ublituximab Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Ublituximab Market

• 11.1. Asia-Pacific Ublituximab Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Ublituximab Market, Segmentation By Formulation Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Ublituximab Market

• 12.1. China Ublituximab Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Ublituximab Market, Segmentation By Formulation Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Ublituximab Market

• 13.1. India Ublituximab Market, Segmentation By Formulation Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Ublituximab Market

• 14.1. Japan Ublituximab Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Ublituximab Market, Segmentation By Formulation Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Ublituximab Market

• 15.1. Australia Ublituximab Market, Segmentation By Formulation Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Ublituximab Market

• 16.1. Indonesia Ublituximab Market, Segmentation By Formulation Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Ublituximab Market

• 17.1. South Korea Ublituximab Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Ublituximab Market, Segmentation By Formulation Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Ublituximab Market

• 18.1. Taiwan Ublituximab Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Ublituximab Market, Segmentation By Formulation Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Ublituximab Market

• 19.1. South East Asia Ublituximab Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Ublituximab Market, Segmentation By Formulation Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Ublituximab Market

• 20.1. Western Europe Ublituximab Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Ublituximab Market, Segmentation By Formulation Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Ublituximab Market

• 21.1. UK Ublituximab Market, Segmentation By Formulation Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Ublituximab Market

• 22.1. Germany Ublituximab Market, Segmentation By Formulation Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Ublituximab Market

• 23.1. France Ublituximab Market, Segmentation By Formulation Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Ublituximab Market

• 24.1. Italy Ublituximab Market, Segmentation By Formulation Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Ublituximab Market

• 25.1. Spain Ublituximab Market, Segmentation By Formulation Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Ublituximab Market

• 26.1. Eastern Europe Ublituximab Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Ublituximab Market, Segmentation By Formulation Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Ublituximab Market

• 27.1. Russia Ublituximab Market, Segmentation By Formulation Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Ublituximab Market

• 28.1. North America Ublituximab Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Ublituximab Market, Segmentation By Formulation Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Ublituximab Market

• 29.1. USA Ublituximab Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Ublituximab Market, Segmentation By Formulation Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Ublituximab Market

• 30.1. Canada Ublituximab Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Ublituximab Market, Segmentation By Formulation Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Ublituximab Market

• 31.1. South America Ublituximab Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Ublituximab Market, Segmentation By Formulation Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Ublituximab Market

• 32.1. Brazil Ublituximab Market, Segmentation By Formulation Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Ublituximab Market

• 33.1. Middle East Ublituximab Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Ublituximab Market, Segmentation By Formulation Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Ublituximab Market

• 34.1. Africa Ublituximab Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Ublituximab Market, Segmentation By Formulation Type, Segmentation By Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Ublituximab Market Regulatory and Investment Landscape

36. Ublituximab Market Competitive Landscape And Company Profiles

• 36.1. Ublituximab Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Ublituximab Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Ublituximab Market Company Profiles
  • 36.3.1. Samsung Biologics Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. TG Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Global Ublituximab Market Competitive Benchmarking And Dashboard

37. Key Mergers And Acquisitions In The Ublituximab Market

39. Ublituximab Market High Potential Countries, Segments and Strategies

• 39.1 Ublituximab Market In 2030 - Countries Offering Most New Opportunities
• 39.2 Ublituximab Market In 2030 - Segments Offering Most New Opportunities
• 39.3 Ublituximab Market In 2030 - Growth Strategies
  • 39.3.1 Market Trend Based Strategies
  • 39.3.2 Competitor Strategies

40. Appendix

• 40.1. Abbreviations
• 40.2. Currencies
• 40.3. Historic And Forecast Inflation Rates
• 40.4. Research Inquiries
• 40.5. The Business Research Company
• 40.6. Copyright And Disclaimer